1. The Intergroup Exemestane Study: a randomised trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen—updated survival analysis;Coombes;Breast Cancer Res Treat,2004
2. Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3,123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial;Jakesz;Breast Cancer Res Treat,2004
3. The economic burden of breast cancer recurrence: findings from a retrospective analysis of health system data;Lamerato;Breast Cancer Res Treat,2004